CRE Homepage About The CRE Advisory Board Newsletter Search Links Representation Comments/Ideas
Data Access
Data Quality
Regulation by Litigation
Regulation by Appropriation
Special Projects
CRE Watch List
OMB Papers
Abstracts and Reviews
Regulatory Review
Voluntary Standards Program
CRE Report Card
Public Docket Preparation
Consumer Response Service
Site Search

Enter keyword(s) to search

®: CRE Regulatory Action of the Week

Comment on CMS' Proposed Rules on Drug Price Transparency
The U.S. Centers for Medicare & Medicaid Services, HHS, has proposed rules that wouldrevise the Federal Health InsurancePrograms for the Aged and Disabled by amending the Medicare Parts A, B, Cand D programs, as well as the Medicaid program, to require direct-to-consumertelevision advertisements ofprescription drugs and biologicalproducts for which payment is availablethrough or under Medicare or Medicaid to include the Wholesale AcquisitionCost (WAC, or ''list price'') of that drugor biological product. To be assured consideration, comments must be received no laterthan 5 p.m. on December 17, 2018.

  • Click here for more details and relevant links.